Investor Relations (IR) Questions: NovaBay Pharmaceuticals NBY
Click here to return to the biotech IRQ Index
Answers received: April 2013
1) When is the last time NBY raised cash through an offering (diluted)?
On December 6, 2012, NovaBay announced the completion of an underwritten public offering of common stock and warrants managed by Lazard Capital Markets, net proceeds were $6.656 million.
2) How much cash (not cash equivalents) does NBY have?
At 12/31/12 NovaBay reported $17.8 million with which to operate our business and clinical operations. These funds were comprised of Cash and cash equivalents ($12.7 million), Short-term investments ($4.1 million) and Accounts Receivable ($0.9 million).
3) What and approximately when is the next known catalyst?
During 2013 NovaBay expects to be in the unique position of announcing a series of advanced clinical trial results with its first-in-class anti-infective, auriclosene(previously known as NVC-422) and commercial marketing partnerships for its wound care product, NeutroPhase®:
· Q2 – Report Phase 2 clinical data from NovaBay’s Urinary Catheter Blockage and Encrustation Trial
· Q3 – Report Phase 2b data from global Impetigo trial being conducted by NovaBay partner Galderma, SA
· Q4 – Report Phase 2b data from global Viral Conjunctivitis trial
· Q2 through Q4 – A series of commercial/marketing partnerships for NeutroPhase are in the works. Additionally, we are applying for registration in a number of countries around the globe.
4) What is NBY's quarterly cash burn?
During 2012, NovaBay’s quarterly cash burn from operations averaged approximately $3.4 million, while average quarterly inflow generated from corporate partner revenues was $1.7 million and financing inflows averaged $2.4 million per quarter. These combined activities resulted in net positive cash flow of $0.7 million per quarter, or $2.732 million for the full year of 2012
5) Does NBY have an existing line of credit and if so how much can they draw against it?
NovaBay does not currently have or plan to have a line of credit.
Best regards,
Tom
Thomas J. Paulson
Chief Financial Officer
1) When is the last time NBY raised cash through an offering (diluted)?
On December 6, 2012, NovaBay announced the completion of an underwritten public offering of common stock and warrants managed by Lazard Capital Markets, net proceeds were $6.656 million.
2) How much cash (not cash equivalents) does NBY have?
At 12/31/12 NovaBay reported $17.8 million with which to operate our business and clinical operations. These funds were comprised of Cash and cash equivalents ($12.7 million), Short-term investments ($4.1 million) and Accounts Receivable ($0.9 million).
3) What and approximately when is the next known catalyst?
During 2013 NovaBay expects to be in the unique position of announcing a series of advanced clinical trial results with its first-in-class anti-infective, auriclosene(previously known as NVC-422) and commercial marketing partnerships for its wound care product, NeutroPhase®:
· Q2 – Report Phase 2 clinical data from NovaBay’s Urinary Catheter Blockage and Encrustation Trial
· Q3 – Report Phase 2b data from global Impetigo trial being conducted by NovaBay partner Galderma, SA
· Q4 – Report Phase 2b data from global Viral Conjunctivitis trial
· Q2 through Q4 – A series of commercial/marketing partnerships for NeutroPhase are in the works. Additionally, we are applying for registration in a number of countries around the globe.
4) What is NBY's quarterly cash burn?
During 2012, NovaBay’s quarterly cash burn from operations averaged approximately $3.4 million, while average quarterly inflow generated from corporate partner revenues was $1.7 million and financing inflows averaged $2.4 million per quarter. These combined activities resulted in net positive cash flow of $0.7 million per quarter, or $2.732 million for the full year of 2012
5) Does NBY have an existing line of credit and if so how much can they draw against it?
NovaBay does not currently have or plan to have a line of credit.
Best regards,
Tom
Thomas J. Paulson
Chief Financial Officer